Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Retained Earnings (2024 - 2025)

Evommune (EVMN) has disclosed Retained Earnings for 2 consecutive years, with -$221.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 45.24% to -$221.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$221.1 million, a 45.24% decrease, with the full-year FY2025 number at -$221.1 million, down 45.24% from a year prior.
  • Retained Earnings was -$221.1 million for Q4 2025 at Evommune, down from -$192.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$152.2 million in Q4 2024 to a low of -$221.1 million in Q4 2025.